Preventing Stroke with Better Sleep: Earn Continuing Education
Earn sleep continuing education credits (CSTEs) from Sleep Review’s July/August 2025 digital edition.
Read More
Author: Sleep Review Staff
New Evidence Supports Xywav’s Benefits for Daytime, Nighttime Symptoms in Narcolepsy, IH
Phase 4 DUET trial and real-world data presented at World Sleep 2025 and Psych Congress 2025 highlight low-sodium Xywav’s impact on sleep continuity, alertness, and cardiometabolic risk profiles in adults with narcolepsy or idiopathic hypersomnia.
Read More
Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio
The $2.1 billion all-cash deal will bring Avadel’s once-nightly oxybate, LUMRYZ, under Alkermes’ umbrella as it advances its orexin agonist pipeline for narcolepsy and other hypersomnolence disorders.
Read More
Sleep Apnea May Amplify GLP-1 Survival Benefits in Type 2 Diabetes
A study of nearly 1.8 million adults with diabetes suggests patients with obstructive sleep apnea derive a 20% greater mortality reduction from GLP-1 therapy than those without the sleep disorder.
Read More
Survey: Americans Are Struggling to Sleep—and Many Are Turning to Unvetted Sources for Help
Durable medical equipment provider Aeroflow Sleep, which specializes in CPAP supplies, today announced the results of a proprietary survey.
Read More